Loading clinical trials...
Loading clinical trials...
The purpose of the study is to address the following hypotheses: the PD-1 inhibitor Sintilimab 200mg for intravenous (IV) administration will be given together with three-week epirubincin, cyclophosph...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
NCT07069595 · Breast Cancer, Residual Disease, and more
NCT06681064 · Breast Cancer, Triple Negative Breast Cancer, and more
NCT05005403 · Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more
NCT06547840 · Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, and more
NCT06451497 · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and more
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions